|
|
|
| Therapeutic effect of Salvia miltiorrhiza on oral submucosal fibrosis in rats |
| YANG Bo, LV Jiao, ZHANG Xuemei, NIE Xiaohan |
| Department of Stomatology,Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing 102218, China |
|
|
|
|
Abstract Objective To study the therapeutic effect of salvia miltiorrhiza on oral submucosal fibrosis in rats. Methods After the establishment of the SD rat OSF model using arecoline smear method, the rats were divided into 6 experimental groups and 1 control group. The experimental group received 5 mg/ml tanshinone ⅡA, tanshinone ⅡB, cryptotanshinone, isocryptotanshinone, salvianolic acid A, and salvianolic acid B, while the control group were treated with physiological saline. After 8 weeks of treatment, the local mucosal lesion area was measured and the local buccal mucosa was stained with HE to observe the pathological changes. The expressions of type Ⅲ collagen, TGF-β1 and IFN-γ were detected. Results The area of oral submucosal fibrosis in the tanshinone ⅡA, cryptotanshinone and isocryptotanshinone groups decareased by 2.72, 1.95, and 1.58 cm2, respectively, and the cure rate was 60%-80%, which was statistically significant compared to the control group.The type Ⅲ collagen in the tanshinone ⅡA, cryptotanshinone, and iso cryptotanshinone groups decreased by 0.06, 0.04, 0.03,TGF-β1 decreased by 0.08, 0.04, 0.05, and IFN-γ increased by 0.06, 0.03, 0.03, with statistically significant differences compared to the control group (P＜0.05).There was no statistically significant difference between the tanshinone ⅡB, salvianolic acid A, and salvianolic acid B groups and the control group. Conclusions Tanshinone ⅡA, Cryptotanshinone and Isocryptotanshinone have therapeutic effects on OSF in rats, while Tanshinone ⅡB, salvianolic acid A and salvianolic acid B do not have therapeutic effects.
|
|
Received: 20 March 2023
|
|
|
|
|
|
| [1] |
Shieh T M, Kavitha L. Immunohistochemical biomarkers in oral submucous fibrosis: a scoping review[J]. Int J Mol Sci,2022,51(7):594-602.
|
| [2] |
Murthy V, Mylonas P, Carey B, et al. Malignant transformation rate of oral submucous fibrosis: a systematic review and meta-analysis[J]. Bio Med Res Int, 2022,11(7):257-271.
|
| [3] |
Shyam S, Fathima J H S, Umesh W, et al. The prevalence of oral squamous cell carcinoma with oral submucous fibrosis[J]. J Oral Path Med, 2021,17(6):1510-1514.
|
| [4] |
Wang L, Tang Z. Immunopathogenesis of oral submucous fibrosis by chewing the areca nut[J]. J Leukocyte Biol, 2022,111(2):469-476.
|
| [5] |
马晓晶, 杨 健, 马桂荣, 等. 中药丹参的现代化研究进展[J]. 中国中药杂志,2022,47(19):5131-5139.
|
| [6] |
Jiang J S, Gu Q C, Feng Z M, et al. The phenolic acids from the plant of Salvia miltiorrhiza[J]. Fitoterapia,2022,159(2):105-119.
|
| [7] |
Yin Z, Wang X, Yang X,et al. Salvia miltiorrhiza in Anti-diabetic Angiopathy[J]. Curr Mol Pharmacol,2021,14(6):960-974.
|
| [8] |
Jia Q, Zhu R, Tian Y, et al. Salvia miltiorrhiza in diabetes: A review of its pharmacology, phytochemistry, and safety[J]. Phytomedicine phy, 2019,58(5):152-160.
|
| [9] |
李 涛.曲安奈德联合丹参酮注射液治疗口腔黏膜下纤维化的临床效果[J]. 临床医学研究与实践,2022,7(15):42-45.
|
| [10] |
张 妮.复方丹参滴丸治疗口腔黏膜下纤维化的作用机制的网络药理学分析及分子对接研究[D].太原: 山西医科大学, 2021.
|
| [11] |
赖 莉,蒋正阳,冯宇鹏,等. 丹参活性成分生物可及性分析[J]. 药学学报,2022,57(8):2435-2444.
|
| [12] |
Hua Z, Wei P.Salvia miltiorrhiza injection promotes the adipogenic differentiation of human adipose-derived stem cells[J]. Plast Reconstr Surg, 2022,149(2):338-339.
|
| [13] |
Wang X, Yang Y,Liu X, et al. Pharmacological properties of tanshinones, the natural products from Salvia miltiorrhiza[J]. Evid Based Compl Alt, 2020,87(1):43-70.
|
| [14] |
杨 博, 符梦凡, 唐瞻贵. 槟榔碱及机械刺激构建大鼠口腔黏膜下纤维化模型[J]. 华西口腔医学杂志,2019,37(3):260-264.
|
| [15] |
唐瞻贵, 成雨熹. 口腔黏膜下纤维性变临床诊治的研究进展[J]. 口腔医学研究, 2022,38(8):705-709.
|
|
|
|
2023, Vol. 34 
